Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Merck 3Q11

Revenues up 8%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 3Q11
 

3Q Revenues: $12.0 billion (+8%)
 

3Q Earnings: $1.7 billion (earnings were $342.0 million 3Q10) 
 

YTD Revenues: $35.8 billion (+5%)
 

YTD Earnings: $4.8 billion (earnings were $1.5 billion YTD10)
 

Comments: Sales growth, including 5% from foreign exchange, was driven by pharmaceutical and animal health sales. Januvia sales were $846.0 million in the quarter (+41%). Gardasil sales were $445.0 million (+41%). Singulair sales were $1.3 billion (+10%). Janumet sales were $350.0 million (+4%). Isentress sales were $343.0 million (+23%). Remicade sales were down 15% in the quarter to $561.0 million, due to the transfer of marketing rights to Johnson & Johnson in Canada, Central and South America, the Middle East, Africa and Asia Pacific. Animal Health sales totaled $826 million in the quarter, up 20%. 2010 results include acquisition-related costs and restructuring costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters